Study of Open Label Losartan in COVID-19

COVID-19 Clinical Trial

Official title:

An Open Label Phase 1 Trial of Losartan for Worsening Respiratory Illness in COVID-19

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04335123
• Other study ID #: STUDY00145514
• Status: Completed
• Phase: Phase 1
• Start date: April 4, 2020
• Est. completion date: August 17, 2020

Study information

• Verified date: May 2021
• Source: University of Kansas Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open label, phase 1 clinical trial to evaluate the safety of losartan in respiratory failure due to COVID-19.

Briefly, 50 patients with COVID-19 and respiratory failure who meet eligibility criteria and agree to participation in the study will be placed on losartan 25 mg daily on study day 0. If parameters are met the dose of losartan will be increased to 50 mg once daily on study day 3. Participants will continue losartan until they experience resolution of respiratory failure (normal oxygen levels on room air), are discharged from the hospital, meet stoppage criteria (detailed below) or complete 14 days of therapy.

Patients and/or surrogate decision maker who do not give consent to treatment will be asked to allow collection of data from their medical record for use as a control group. We will also collect medical information relating to safety criteria on historical controls treated at the University of Kansas Hospital in the 30 days prior to the study start date (3/25/2020) and during the study period.

Description:

This is an open label, phase 1 clinical trial to evaluate the safety of losartan in respiratory failure due to COVID-19.

Clinical Trial setup:

Detailed inclusion and exclusion criteria are listed below. Briefly, 50 patients with COVID-19 and respiratory failure who meet criteria and agree to participation in the study will be placed on losartan 25 mg daily on study day 0. If parameters are met the dose of losartan will be increased to 50 mg once daily on study day 3. Participants will continue losartan until they experience resolution of respiratory failure (normal oxygen levels on room air), are discharged from the hospital, meet stoppage criteria (detailed below) or complete 14 days of therapy.

Patients and/or surrogate decision maker who do not give consent to treatment will be asked to allow collection of data from their medical record for use as a control group.

Stoppage criteria for losartan

• Hyperkalemia (persistent values >5.5 mM recorded on at least 2 readings).

• Worsening renal function (Cockcroft-Gault <30 mL/min/1.73 m2) or urinary output <20 mL/h.

• Skin rashes, palpitations or other moderate or severe adverse events (interference with usual daily activities) without clear explanation should warrant immediate cessation of treatment and notification of study personnel.

• Development of sustained hypotension defined as SBP <90 mmHg, DBP <60 mmHg recorded on at least two readings 30 min apart or use of norepinephrine >0.1 µg/kg/min.

• Any change in monitor lab parameters deemed significant and potentially related to study drug by the Investigator.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 34
• Est. completion date: August 17, 2020
• Est. primary completion date: June 21, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age >18 years admitted to the University of Kansas Health System.

• Confirmation of infection with SARS-CoV-2 by PCR testing.

• Hypoxic respiratory failure Requiring mechanical ventilation or oxygen OR a SpO2 =94% on room air or a PaO2/FiO2 (P/F) ratio <300 OR tachypnea (respiratory rate =24 breaths/min). Criteria to be met within 48 hours prior to Day 0.

• Other concomitant medications such as antivirals and hydroxychloroquine are allowed.

• Participants prescribed standard of care (SOC) losartan (25mg QD) within 48 hours of consenting may be considered for enrollment if eligibility criteria are met based on EMR data assessment, i.e. no other ARB or ACE prior to SOC medication administration. If participant is eligible and signs consent form, investigational losartan 25mg QD will be ordered to replace SOC prescription on the following scheduled dose.

Exclusion Criteria:

• Pregnancy.

• Respiratory failure due to a process other than COVID-19.

• Intolerance to ARBs.

• Previous treatment with an ARB or ACE inhibitor (see exception in inclusion criteria).

• Current chronic use of medication with known interactions with losartan including NSAIDs (intermittent prior use is acceptable), potassium supplementation aliskiren.

• Blood pressure less than 90 mm Hg systolic or 60 mm Hg diastolic recorded on at least two readings 30 min apart.

• Need for vasopressors, unless norepinephrine =0.1 µg/kg/min

• Hyperkalemia (serum K+ >5.5 mM).

• Known cardiac failure (left ventricular ejection fraction =35%), renal insufficiency (Cockcroft-Gault <30 mL/min/1.73 m2 or urinary output <20 mL/h), hepatic failure (LFTs > 5x normal upper limit).

• Known renal artery stenosis.

• Neurological, psychiatric, endocrine or neoplastic diseases that are judged to interfere with participation in the study.

• On another interventional trial (including one for COVID-19) that excludes participation.

Related Conditions & MeSH terms

• COVID-19

Intervention

Drug:
• Losartan
25 mg QD from day 0 to day 3. Dose escalation to 50 mg QD until study completion

Locations

Country	Name	City	State
United States	University of Kansas Medical Center	Kansas City	Kansas

Sponsors (1)

Lead Sponsor	Collaborator
University of Kansas Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with treatment-related adverse events as assessed by protocol definition of AE	Safety will be reported based on Protocol defined AEs.; For the purpose of this protocol, an AE will be defined as as any untoward medical occurrence in a subject during the study listed under DMSB - Anticipated Adverse Events and Grading Scale section of this protocol as well as safety monitoring data listed on protocol table 1 as well as stoppage criteria for losartan.; The event does not necessarily have a causal relationship with the treatment. AEs will be collected for both study groups, treatment and control from the time the ICF is signed until the subject completes study participation.	14 days of losartan treatment
Secondary	Number of days on supplemental oxygen in respiratory failure due to COVID-19	Number of days on supplemental oxygen in respiratory failure due to COVID-19	14 days of losartan treatment
Secondary	Incidence of mechanical ventilation use	Incidence of mechanical ventilation use	14 days of losartan treatment
Secondary	Days on mechanical ventilation	Days on mechanical ventilation	14 days of losartan treatment
Secondary	Incidence of non-invasive positive pressure ventilation or heated high flow nasal cannula use	Incidence of non-invasive positive pressure ventilation or heated high flow nasal cannula use	14 days of losartan treatment
Secondary	Days on non-invasive positive pressure ventilation or high flow nasal cannula	Days on non-invasive positive pressure ventilation or high flow nasal cannula	14 days of losartan treatment
Secondary	Incidence of transfer to ICU from non-ICU hospital bed	Incidence of transfer to ICU from non-ICU hospital bed	14 days of losartan treatment
Secondary	ICU length of stay (days)	ICU length of stay (days)	14 days of losartan treatment
Secondary	30-day mortality rate	30-day mortality rate	30 days after diagnosis of COVID-19
Secondary	Hospital length of stay (days)	Hospital length of stay (days)	14 days of losartan treatment
Secondary	Cumulative incidence of severe adverse events	Cumulative incidence of severe adverse events	14 days of losartan treatment
Secondary	Cumulative incidence of adverse events	Cumulative incidence of adverse events	14 days of losartan treatment
Secondary	Change from baseline in oxygenation	Change from baseline in oxygenation	14 days of losartan treatment
Secondary	Incidence of medications with possible antiviral activity (hydroxychloroquine, lopinavir/ritonavir, ribavirin or remdesivir) or adjunctive therapy use (e.g., tocilizumab)	Incidence of medications with possible antiviral activity (hydroxychloroquine, lopinavir/ritonavir, ribavirin or remdesivir) or adjunctive therapy use (e.g., tocilizumab)	14 days of losartan treatment
Secondary	Incidence (and length in days) of extracorporeal membrane oxygenation use	Incidence (and length in days) of extracorporeal membrane oxygenation use	14 days of losartan treatment
Secondary	Incidence (and length in days) of renal replacement therapy use	Incidence (and length in days) of renal replacement therapy use	14 days of losartan treatment
Secondary	Intolerance of high dose (50mg) losartan after tolerating 25mg	Intolerance of high dose (50mg) losartan after tolerating 25mg	14 days of losartan treatment